Compare
Travere Therapeutics, Inc. vs Nature's Sunshine Products Inc vs BridgeBio Pharma, Inc. vs Mirum Pharmaceuticals, Inc.
| Latest fiscal year | Travere Therapeutics, Inc. TVTX | Nature's Sunshine Products Inc NATR | BridgeBio Pharma, Inc. BBIO | Mirum Pharmaceuticals, Inc. MIRM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $490.73M | $480.14M | $502.08M | $521.31M |
| Revenue growth (YoY) | +110.5% | +5.7% | +126.3% | +54.7% |
| Gross margin | n/a | 72.4% | n/a | n/a |
| Operating margin | -12.8% | 5.2% | -104.2% | -4.2% |
| Net margin | -5.2% | 4.3% | -146.0% | -4.5% |
| Net income | -$25.55M | $20.45M | -$732.94M | -$23.36M |
| EPS (Diluted) | -$0.29 | $1.06 | -$3.78 | -$0.47 |
| Operating cash flow | $37.78M | $35.32M | -$445.91M | $55.83M |
| Free cash flow | n/a | $28.84M | -$447.01M | $54.87M |
| Cash & equivalents | $93.03M | $93.89M | $570.12M | $296.68M |
| Total assets | $605.19M | $261.15M | $936.02M | $842.81M |
| Total liabilities | $490.36M | $99.59M | $3.01B | $528.12M |
| Shareholders' equity | $114.83M | $161.55M | -$2.09B | $314.69M |
| Return on year-end equity | -22.2% | 12.7% | n/a | -7.4% |
| Shares outstanding | 90.92M | 17.51M | 194.77M | 51.90M |
Revenue, most recent five fiscal years
| Fiscal year | Travere Therapeutics, Inc. | Nature's Sunshine Products Inc | BridgeBio Pharma, Inc. | Mirum Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $490.73M Ended 2025-12-31 | $480.14M Ended 2025-12-31 | $502.08M Ended 2025-12-31 | $521.31M Ended 2025-12-31 |
| 1 year earlier | $233.18M Ended 2024-12-31 | $454.36M Ended 2024-12-31 | $221.90M Ended 2024-12-31 | $336.89M Ended 2024-12-31 |
| 2 years earlier | $145.24M Ended 2023-12-31 | $445.32M Ended 2023-12-31 | $9.30M Ended 2023-12-31 | $186.37M Ended 2023-12-31 |
| 3 years earlier | $109.46M Ended 2022-12-31 | $421.91M Ended 2022-12-31 | $77.65M Ended 2022-12-31 | $77.06M Ended 2022-12-31 |
| 4 years earlier | $131.84M Ended 2021-12-31 | $444.08M Ended 2021-12-31 | $69.72M Ended 2021-12-31 | $19.14M Ended 2021-12-31 |